RIVASA 81 MG EC TABLET (DELAYED-RELEASE)

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

ACETYLSALICYLIC ACID

Dostupné s:

LABORATOIRE RIVA INC.

ATC kód:

B01AC06

INN (Mezinárodní Name):

ACETYLSALICYLIC ACID

Dávkování:

81MG

Léková forma:

TABLET (DELAYED-RELEASE)

Složení:

ACETYLSALICYLIC ACID 81MG

Podání:

ORAL

Jednotky v balení:

1000

Druh předpisu:

OTC

Terapeutické oblasti:

SALICYLATES

Přehled produktů:

Active ingredient group (AIG) number: 0101169013; AHFS:

Stav Autorizace:

APPROVED

Datum autorizace:

2014-02-17

Charakteristika produktu

_RIVASA 81 MG EC - Product Monograph _
_ _
_Page 1 of 44 _
PRODUCT MONOGRAPH
RIVASA 81 MG EC
Acetylsalicylic
Acid Delayed Release Tablets
81 mg
USP
Platelet aggregation inhibitor
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville,
Quebec
J7C 3V4
www.labriva.com
Date of Preparation:
February 17, 2014
Date of Revision:
September 14, 2022
Control Number: 266709
_RIVASA 81 MG EC - Product Monograph _
_ _
_Page 2 of 44 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
INDICATIONS AND CLINICAL USE
........................................................................
3
CONTRAINDICATIONS
............................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................
4
ADVERSE
REACTIONS.............................................................................................
6
DRUG INTERACTIONS
.............................................................................................
7
DOSAGE AND ADMINISTRATION
..........................................................................
9
OVERDOSAGE
.........................................................................................................10
ACTION AND CLINICAL
PHARMACOLOGY.........................................................11
STORAGE AND STABILITY
....................................................................................12
DOSAGE FORMS, COMPOSITION AND PACKAGING
..........................................12
PART II: SCIENTIFIC INFORMATION
..........................................................................
13
PHARMACEUTICAL INFORMATION
.....................................................................13
CLINICAL TRIALS
...................................................................................................14
DETAILED
PHARMACOLOGY.........